Yet employers still pay for those initial months of expensive medication
Eli Lillys retatrutide, a triple hormone receptor agonist, has demonstrated an average weight loss of 28.3% over 80 weeks on the highest dose in Phase 3 trials
In 2025, the company reported a modest +1.29% YoY revenue growth, shaped largely by its core portfolio: Keytruda ($31.68B) continues to dominate as one of the worlds top-selling oncology drugs with expanding indications, Gardasil/Gardasil 9 ($5.23B) remains a key growth driver in vaccines despite some demand fluctuations, and Januvia/Janumet ($2.54B) continues to decline as generic competition intensifies
Symptoms include nausea, vomiting, bloating, feeling full quickly, and abdominal pain
#GLP1 #WeightLossJourney #GLP1Tips #MedicalWeightLoss | Charlotte Hodges, MD
You may see deeper body weight and fat loss, improved glucose control, and intensified changes but those gains come with increased need for supervision and support